Company
GENESI-X1 v1.0: a variant-aware framework for PCR and qPCR assay design
Nov 21, 2026 · 5 min read · GeneSI Lab
Our first technical report introduces an in-silico prototype that ranks primer and probe designs by specificity, population variation and thermodynamics.
We have released the GENESI-X1 v1.0 technical report, a pre-peer-review computational study describing an in-silico framework for variant-aware polymerase chain reaction (PCR) and quantitative PCR (qPCR) assay design. This note introduces why single-reference primer design breaks down on human populations, how GENESI-X1 works, and what our simulation benchmark shows.
The problem with single-reference primer design
Standard primer design software optimizes melting temperature (Tm), GC percentage and self-complementarity against a single haploid reference genome. Conventional tools therefore ignore population genetic variation and can miss homology across paralog gene families. They also rank pairs one locus at a time without multiplex awareness and rarely explain rankings.
In real samples, human genomes differ substantially from any single reference sequence. Controlled qPCR studies demonstrate that single-nucleotide mismatches delay quantification cycles (Cq) and reduce amplification efficiency. Mismatches within the 3′-terminal 5 nucleotides (nt) of a primer can even cause complete allelic dropout.
Modern population catalogs such as gnomAD v4.1 span 807,162 individuals across 730,947 exomes and 76,215 genomes, exposing frequent polymorphisms across medically important loci. Paralog families also require careful 3′-end discrimination to prevent off-target amplification. Examples include HBB with HBD, HBG1, HBG2 and HBE1; KRAS with NRAS and HRAS; EGFR with ERBB2 to ERBB4; and TP53 with TP63 and TP73.
What GENESI-X1 does
GENESI-X1 (Genomic Engine for Nucleic-acid Evaluation, Specificity, and Intelligent Assay Design, Generation X, version 1.0) integrates seven modules into a deterministic Snakemake pipeline. Those modules are IngestCore, VarShield, CandGen, BlastSpec with ViennaRNA biophysics, ThermoSpec-LM, MultiPlexOpt and ExplainX, paired with ReportForge outputs.
Together, these modules ingest annotations, score position-weighted variant exposure, generate dual-stream primer-probe candidates and screen off-targets across RefSeq RNAs and paralogs. ThermoSpec-LM ranks candidates using 78 features across 6 domains under 8-fold leave-one-gene-out cross-validation. Across five seeds, LightGBM achieved nDCG-5 of 0.9932 plus or minus 0.0010 and Spearman 0.9544.
How we tested it
We evaluated GENESI-X1 v1.0 in silico across 8 human disease genes: HBB, CFTR, BRCA1, BRCA2, TP53, EGFR, KRAS and G6PD. The benchmark covers 24 exon hotspot windows of 463 to 1,301 bp (19,690 bp in total) on GRCh38.p14. It spans 11 paralogs, 96 ClinVar hotspots and 186,716 RefSeq RNAs. It also tracks 14,001 gnomAD v4.1.0 variants, including 102 at AF of at least 0.01 and 205 at AF of at least 0.001.
Data were curated on 2026-11-20 and 2026-11-21 from Ensembl Release 116, MANE v1.5 and RefSeq RS_2025_08 with SHA-256 verification. We compared GENESI-X1 against four baselines: default Primer3 (B1), masked and BLAST-screened Primer3 (B2) and a linear heuristic (B3). We also included 18 primer pairs from 15 open-access wet-lab publications across 7 genes (B4).
What we found in silico
In simulation, GENESI-X1 reached a mean Reference Quality Score (RQS) of 0.8743 (95% confidence interval 0.853 to 0.896). By comparison, B1 scored 0.7664, B2 scored 0.7924 and B3 scored 0.8601. RQS improved in 8 of 8 genes versus each baseline (exact gene-level p = 0.007812). Holm-corrected Wilcoxon p-values were 3.58e-7 versus B1 and B2, and 0.0138 versus B3.
Default Primer3 (B1) overlapped common gnomAD variants (AF of at least 0.01) at 29.2% of loci, whereas B2, B3 and GENESI-X1 reached 100.0% common-variant safety. ClinVar hotspot capture rose from 41.7% for B1 and B2 and 95.8% for B3 to 100.0% for GENESI-X1 (mean 2.04 hotspots per locus). Across all methods, 23 of 24 loci (95.8%) had no unintended amplicons, with one predicted hit remaining on EGFR_L2_Ex20.
Exact diploid Poisson-binomial calculations were verified against 1,000,000 simulated individuals per locus. Predicted strict 3′-seed or multi-mismatch dropout fell 12.0-fold from 24.53 per 10,000 individuals under B1 to 2.05 under GENESI-X1 (versus 3.54 for B2 and 1.50 for B3). Any oligo-footprint mismatch fell 51.7-fold from 614.58 per 10,000 under B1 to 11.89 under GENESI-X1.
- Mean RQS improved in 8 of 8 genes: GENESI-X1 0.8743 versus B1 0.7664, B2 0.7924 and B3 0.8601.
- 100.0% common-variant safety and 100.0% ClinVar hotspot capture across 24 loci in simulation.
- Any oligo-footprint mismatch rate dropped 51.7-fold from 614.58 to 11.89 per 10,000 simulated individuals.
What comes next
GENESI-X1 v1.0 is an in-silico research prototype, not a medical device, and no wet-lab experiments, no patient tests and no clinical validation have been performed. RQS is author-defined, and our benchmark covers only 8 genes (a pooled 15-test correction yields p = 0.1172). Our BLAST index also omits deep introns, and the frozen DNA model is non-commercial.
Next, we plan to execute a MIQE-aligned wet-lab validation synthesizing HPLC-purified primers and dual-labeled 5′-FAM and 3′-BHQ1 probes for the proposed 8-plex panel. Standard curves, paralog controls and variant-template stress tests will measure amplification efficiency, Cq reproducibility and limit of detection directly.
These results are computational (in silico). GENESI-X1 v1.0 is a research prototype, not a medical device, and no wet-lab or clinical validation has been performed. For research use only.
Related
Questions about this work? Email contact@genesilabs.xyz